A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy
将 Omega-3 脂肪酸创造性地整合到胰腺癌化疗中
基本信息
- 批准号:8824063
- 负责人:
- 金额:$ 16.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-01-01 至 2016-12-31
- 项目状态:已结题
- 来源:
- 关键词:AbraxaneAcuteAddressAdverse eventAffectAlbumin-Stabilized Nanoparticle PaclitaxelAlbuminsAngiogenesis InhibitorsAnimal ModelAntineoplastic AgentsBindingBiodistributionBiologyCachexiaCancer BiologyCancer DiagnosticsCancer EtiologyCancer ModelCancer PatientCancer cell lineCessation of lifeChemistryChemotherapy-Oncologic ProcedureClinicalClinical TrialsDHA-PaclitaxelDataDeaminationDesire for foodDesmoplasticDevelopmentDocosahexaenoic AcidsDoseDrug KineticsEmulsionsEvaluationExcisionExcretory functionFatty AcidsFish OilsFoundationsFutureGenerationsGoalsGovernmentHumanInfusion proceduresIntravenousInvestigational New Drug ApplicationInvestigational TherapiesKRAS2 geneLeadLegal patentMalignant NeoplasmsMalignant neoplasm of pancreasMaximum Tolerated DoseMetabolismMethodsMissionMusNatureNude MiceNutritionalOmega-3 Fatty AcidsOperative Surgical ProceduresOutcomePaclitaxelPalliative CarePancreatic Ductal AdenocarcinomaPatientsPersonsPharmacologic SubstancePreventionPropertyPublic HealthQuality of lifeRelative (related person)ReportingResearchRodent ModelSafetyScientistSeriesSolid NeoplasmStructureSurvival RateSymptomsTestingTimeTotal Parenteral NutritionToxic effectToxicity TestsTransgenic MiceTranslationsWeightWorkcancer therapychemotherapycytotoxiccytotoxicityeffective therapyexperiencegemcitabinegemzarhuman diseaseimprovedinnovationmortalitymouse modelneoplastic cellnovelnovel strategiespancreatic cancer cellspancreatic neoplasmpreclinical efficacypreclinical evaluationpreclinical safetypublic health relevancesafety testingstandard of caretumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer death in the U.S., with a 5-year survival rate of only 4-5%. Although significant progress has been made in the past several decades to reduce the overall mortality rate of cancer, an effective treatment for pancreatic cancer remains elusive. Only ~10% of pancreatic cancer patients are suitable for surgical resection, and the remainder is offered palliative treatment to simply extend or improve their quality of life. Approximately 85% of all pancreatic cancer patients suffer from cachexia, a devastating symptom symbolized by the loss of appetite, weight, and quality of life. The standard of care of advanced pancreatic cancer patients has been the single agent chemotherapy with gemcitabine (i.e., Gemzar(R)), which offers a survival advantage of 2-3 months compared to no treatment, and only < 25% of pancreatic cancer patients are responders to it. Our long-term goal is to improve the clinical outcomes of pancreatic cancer therapy. The current proposal combines the expertise of a pharmaceutical scientist experienced in cancer experimental therapy, a cancer biologist with expertise in pancreatic cancer biology and models, and a nutritional scientist with expertise in the chemistry and biology of omega-3 polyunsaturated fatty acids (PUFAs). Data from many clinical trials showed that fish oil rich in omega-3 PUFAs is beneficial in alleviating pancreatic cancer-related cachexia. However, there is no clear clinical evidence supporting the antitumor activity omega-3 PUFAs against pancreatic ductal adenocarcinoma. Our recent promising preliminary data demonstrated that a unique integration of omega-3 PUFAs into gemcitabine therapy significantly improves the antitumor activity of gemcitabine in mouse models of pancreatic cancer. The overall objective of the present application is to comprehensively test the safety and efficacy of this unique integration in mouse models. The primary innovative aspect of this application is the novel method of utilizing omega-3 fatty acids in improving the efficacy of gemcitabine in pancreatic cancer therapy. The proposed research is significant because it addresses the urgent need to improve the overall survival and the quality of life of pancreatic cancer patients (e.g., alleviation of cachexia). Study findings will provide the initial underpinnings for future translation of this innovation into clinical trials, with the ultimate goal of establishing a highl effective approach to pancreatic cancer chemotherapy.
描述(申请人提供):胰腺癌是美国第四大癌症死亡原因,5年生存率仅为4-5%。尽管过去几十年在降低癌症总体死亡率方面取得了重大进展,但胰腺癌的有效治疗方法仍然难以实现。只有约 10% 的胰腺癌患者适合手术切除,其余患者则接受姑息治疗,以延长或改善他们的生活质量。大约 85% 的胰腺癌患者患有恶病质,这是一种破坏性症状,表现为食欲、体重和生活质量下降。晚期胰腺癌患者的护理标准是吉西他滨(即 Gemzar(R))单药化疗,与不治疗相比,其生存期优势为 2-3 个月,并且只有 < 25% 的胰腺癌患者对此有反应。我们的长期目标是改善胰腺癌治疗的临床结果。目前的提案结合了一位在癌症实验治疗方面经验丰富的药物科学家、一位在胰腺癌生物学和模型方面拥有专业知识的癌症生物学家以及一位在 omega-3 多不饱和脂肪酸 (PUFA) 化学和生物学方面拥有专业知识的营养科学家的专业知识。许多临床试验的数据表明,富含 omega-3 PUFA 的鱼油有助于缓解胰腺癌相关的恶病质。然而,没有明确的临床证据支持 omega-3 PUFA 对胰腺导管腺癌的抗肿瘤活性。我们最近令人鼓舞的初步数据表明,将 omega-3 PUFA 独特地整合到吉西他滨治疗中可显着提高吉西他滨在小鼠胰腺癌模型中的抗肿瘤活性。本申请的总体目标是在小鼠模型中全面测试这种独特整合的安全性和有效性。该应用的主要创新点是利用omega-3脂肪酸提高吉西他滨在胰腺癌治疗中的疗效的新方法。拟议的研究意义重大,因为它解决了提高胰腺癌患者的总体生存率和生活质量(例如减轻恶病质)的迫切需要。研究结果将为这项创新未来转化为临床试验提供初步基础,最终目标是建立一种高效的胰腺癌化疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZHENGRONG CUI其他文献
ZHENGRONG CUI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ZHENGRONG CUI', 18)}}的其他基金
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy
将 Omega-3 脂肪酸创造性地整合到胰腺癌化疗中
- 批准号:
8991305 - 财政年份:2015
- 资助金额:
$ 16.86万 - 项目类别:
An innovative approach to improve the activity of an aluminum-containing adjuvant
提高含铝佐剂活性的创新方法
- 批准号:
8605172 - 财政年份:2013
- 资助金额:
$ 16.86万 - 项目类别:
An innovative approach to improve the activity of an aluminum-containing adjuvant
提高含铝佐剂活性的创新方法
- 批准号:
8493404 - 财政年份:2013
- 资助金额:
$ 16.86万 - 项目类别:
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine
使用肿瘤靶向合成 dsRNA 和吉西他滨的联合治疗
- 批准号:
7939086 - 财政年份:2009
- 资助金额:
$ 16.86万 - 项目类别:
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine
使用肿瘤靶向合成 dsRNA 和吉西他滨的联合治疗
- 批准号:
8111826 - 财政年份:2008
- 资助金额:
$ 16.86万 - 项目类别:
Topical DNA immunization by modifying the hair follicle cycle
通过改变毛囊周期进行局部 DNA 免疫
- 批准号:
8056314 - 财政年份:2008
- 资助金额:
$ 16.86万 - 项目类别:
Overcoming pancreatic tumor resistance to gemcitabine
克服胰腺肿瘤对吉西他滨的耐药性
- 批准号:
8856509 - 财政年份:2008
- 资助金额:
$ 16.86万 - 项目类别:
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine
使用肿瘤靶向合成 dsRNA 和吉西他滨的联合治疗
- 批准号:
8043762 - 财政年份:2008
- 资助金额:
$ 16.86万 - 项目类别:
Topical DNA immunization by modifying the hair follicle cycle
通过改变毛囊周期进行局部 DNA 免疫
- 批准号:
7533889 - 财政年份:2008
- 资助金额:
$ 16.86万 - 项目类别:
Overcoming pancreatic tumor resistance to gemcitabine
克服胰腺肿瘤对吉西他滨的耐药性
- 批准号:
8711300 - 财政年份:2008
- 资助金额:
$ 16.86万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 16.86万 - 项目类别:
Operating Grants